Literature DB >> 7884857

Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein.

G Pancino1, L Camoin, P Sonigo.   

Abstract

In the transmembrane envelope glycoprotein (TM) of lentiviruses, including human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus (FIV), two cysteine residues, conserved in most retroviruses, are thought to form a loop containing five to seven amino acids. These elements make up a B-cell epitope recognized by nearly 100% of sera from infected patients or animals, designated the principal immunodominant domain (PID). The PID amino acid sequences are highly conserved between isolates of the same lentivirus but are unrelated, except for the two cysteines, when divergent lentiviruses are compared. The aim of this study was to analyze the relationship between amino acid sequence in the PID and envelope function. We introduced two kinds of mutations in the PID of FIV: mutations which impeded the formation of a loop and mutations which substituted the sequence of FIV with the corresponding sequences from other lentiviruses, HIV-1, visna virus, and equine infectious anemia virus. We analyzed antibody recognition, processing, and fusogenic properties of the modified envelopes, using two methods of Env expression: a cell-free expression system and transfection of a feline fibroblast cell line with gag-pol-deleted FIV proviruses. Most mutations in the PID of FIV severely affected envelope processing and abolished syncytium formation. Only the chimeric envelope containing the HIV-1 PID sequence was correctly processed and maintained the capacity to induce syncytium formation, although less efficiently than the wild-type envelope. We computed three-dimensional structural models of the PID, which were consistent with mutagenesis data and confirmed the similarity of FIV and HIV-1 PID structures, despite their divergence in amino acid sequence. Considering these results, we discussed the respective importance of selection exerted by functional requirements or host antibodies to explain the observed variations of the PIDs in lentiviruses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884857      PMCID: PMC188877     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Conformational sampling using high-temperature molecular dynamics.

Authors:  R E Bruccoleri; M Karplus
Journal:  Biopolymers       Date:  1990-12       Impact factor: 2.505

2.  Analysis of equine humoral immune responses to the transmembrane envelope glycoprotein (gp45) of equine infectious anemia virus.

Authors:  Y H Chong; J M Ball; C J Issel; R C Montelaro; K E Rushlow
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.

Authors:  E Helseth; U Olshevsky; C Furman; J Sodroski
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

4.  Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy.

Authors:  M B Oldstone; A Tishon; H Lewicki; H J Dyson; V A Feher; N Assa-Munt; P E Wright
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

5.  Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus.

Authors:  M Saltarelli; G Querat; D A Konings; R Vigne; J E Clements
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

6.  Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity.

Authors:  W J Syu; W R Lee; B Du; Q C Yu; M Essex; T H Lee
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Detection of B epitopes on the p24 gag protein of feline immunodeficiency virus by monoclonal antibodies.

Authors:  S Lombardi; M Bendinelli; C Garzelli
Journal:  AIDS Res Hum Retroviruses       Date:  1993-02       Impact factor: 2.205

8.  Processing of the glycoprotein of feline immunodeficiency virus: effect of inhibitors of glycosylation.

Authors:  E B Stephens; E Monck; K Reppas; E J Butfiloski
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein.

Authors:  P L Earl; B Moss; R W Doms
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

10.  Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing.

Authors:  R L Willey; T Klimkait; D M Frucht; J S Bonifacino; M A Martin
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

View more
  11 in total

1.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.

Authors:  J Richardson; A Moraillon; S Baud; A M Cuisinier; P Sonigo; G Pancino
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.

Authors:  R Merat; H Raoul; T Leste-Lasserre; P Sonigo; G Pancino
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Retention of viral infectivity after extensive mutation of the highly conserved immunodominant domain of the feline immunodeficiency virus envelope.

Authors:  G Pancino; P Sonigo
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein.

Authors:  R J Center; B Kobe; K A Wilson; T Teh; G J Howlett; B E Kemp; P Poumbourios
Journal:  Protein Sci       Date:  1998-07       Impact factor: 6.725

7.  Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein.

Authors:  Simone Giannecchini; Armida Di Fenza; Anna Maria D'Ursi; Donatella Matteucci; Paolo Rovero; Mauro Bendinelli
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 8.  Feline immunodeficiency virus in South America.

Authors:  Bruno M Teixeira; Mitika K Hagiwara; Juliano C M Cruz; Margaret J Hosie
Journal:  Viruses       Date:  2012-03-14       Impact factor: 5.818

9.  Interaction of short modified peptides deriving from glycoprotein gp36 of feline immunodeficiency virus with phospholipid membranes.

Authors:  Gerardino D'Errico; Giuseppe Vitiello; Anna Maria D'Ursi; Derek Marsh
Journal:  Eur Biophys J       Date:  2009-05-05       Impact factor: 1.733

10.  Structural basis of antiviral activity of peptides from MPER of FIV gp36.

Authors:  Manuela Grimaldi; Ilaria Stillitano; Giuseppina Amodio; Angelo Santoro; Michela Buonocore; Ornella Moltedo; Paolo Remondelli; Anna Maria D'Ursi
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.